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Introduction
Animal safety testing for new medicines is arguably the most difficult use of non-human animals (hereinafter referred to as animals) to challenge, for two reasons: first, it is required by governments (regulatory testing); second, pro tecting patients is a vital goal, and it seems intuitively obvious that animal tests must protect patients. Animal testing became institutionalized in the mid twentieth century (Parke, 1994 ) in response to early drug disasters, with the aim of preventing further tragedies. However, even the laudable aim of protecting patients cannot justify animal testing, unless it is the most effec tive means to ensure the safety of medicines. European Union (EU) law (Euro pean Parliament, 2010, Directive 2010/63/EU) states that animals must not be used if a non-animal method could achieve the same purpose. So, it is crucial to know how well animal tests predict the safety of medicines, and whether any other methods are equally or more predictive. In addition to the question of predictive value, other important issues must also be taken into consider ation, including the efficiency of different methods in terms of time and costs; and the ethical acceptability of using animals, if their use is deemed to be of irreplaceable value.
The issue of whether animals should be used as human surrogates for safety testing is highly contentious; individual views range from no use of animals (Clemence and Leaman, 2016) . In the United States (us), a 2017 Gallup poll found that 44% of adults considered medical testing on animals to be morally wrong (Jones and Saad, 2017) . A 2015 survey by the us Pew Centre found that 50% of citizens "oppose the use of animals in scientific research" (Pew Research Center, 2015 (Leppard, 2006) . TGN1412 was shown to be safe in monkeys at doses 500 times higher than those that nearly proved fatal to the volunteers (St. Clair, 2008 ( Sharav, 2016 (Bisserbe, 2016) . The drug had been tested in mice, rats, dogs, and mon keys, with few ill effects, despite doses up to 650 times stronger than those giv en to the volunteers (Temporary Specialist Scientific Committee, TSSC, 2016) . A subsequent study indicates that an off-target effect, which can be species dependent, may explain why animal tests in multiple species did not identify the deadly neurological effects (van Esbroeck et al., 2017 (Thompson, 1994 (European Commission, 2008) , and over 125,000 in the us (Light, 2015) . In addition to this devastating human cost, the financial cost of AD Rs is astronomical, calculated at €79 billion per annum in the EU (European Commission, 2008 (Rawson, 2013 (Lasser et al., 2002 (Herper, 2012 (Light, 2015 (Nair, 2015) . Clearly the record of animal tests in predicting safety is poor. Another example that illustrates the dangers of both misleading preclini cal animal studies and non-publication of clinical trials is lorcainide, which is estimated to have killed over 100,000 people in the us alone over the course of the 1980s (Bruckner and Ellis, 2017 (Hampton, 2015) .
An important point that must be made is the difference between predict ing the presence or the absence of toxicity. It seems intuitively obvious that if a compound is overtly toxic for an animal, it is not unreasonable to suspect
that it will also be toxic in humans. In a series of studies, Bailey, Thew and Balls (2013 examined the likelihood that such suspicions would be cor rect. They analyzed a data set of 2,366 drugs, for which both animal and human data are available, in the most comprehensive analysis of publicly available animal toxicity data ever compiled. Crucially, they used the appropriate statisti cal metrics of likelihood ratios, for the first time, to question critically the value of the use of the main preclinical animal species (i.e., rats, mice, rabbits, dogs, and monkeys) in the testing of new human pharmaceuticals. They found that the presence of toxicity in animal tests indeed shares some degree of correla tion ( above random chance) with the presence of toxicity in humans, although such correlation is too variable to be regarded as predictive, as has been dem onstrated by many previous studies (Fourches et al., 2010; Geerts, 2009; Green, 2015; Hackam and Redelmeier, 2006; Heywood, 1990; Igarashi, 1994; Ioannidis, 2012; Knight et al., 2006; Matthews, 2008; Pound et al., 2004; Pound and Brack en, 2014; Perel et al., 2007; Salsburg, 1983; Seouk et al., 2013; Spriet-Pourra and Auriche, 1994; Wall and Shani, 2008, van Meer et al., 2012 ( van Meer, 2012 (Capdeville, 2002) . (Carthew, 1995) . Evidence for this may also be gleaned from drugs introduced before rigorous safety testing became mandatory. For example, aspirin, introduced over a hundred years ago, has proved useful for pain treatment ever since, but it is highly doubtful it would ever have appeared had it been subjected to modem animal-based safety testing (Hartung, 2009 (Cortinovis and Caloni, 2016 (Hare, 1982 (Parke, 1994 (Hutchinson and Kirk, 2011) ; all putative disease-modifying treatments ( more than 300) for Alzheimer's disease to date (Langley, 2014; Lowe, 2017 ) ; more than 100 candidate AIDS vaccines, all of which were effective in non human primates, as well as other animal models (Sheets et al., 2016) (Seok et al., 2013 (Harris, 2017) . This reproducibility crisis is now receiving much attention, and many initiatives have begun to attempt to improve standards and the quality of animal research and reporting (Harris, 2017) . However, a review of developments in the field of stroke found that, de spite researchers' adherence to recommendations intended to improve the quality of preclinical stroke studies for over 10 years, there is no evidence of an increased rate of successful translation (Sutherland et al., 2012) (Xu et al., 2008) . This could enable the detection of poten tial rare ADRs that are currently unpredictable (Kenna, 2017 (Baker, 2011 ) . (Huang et al., 2016) . The human in vitro data were mainly assessed against rodent data, as human in vivo data are sparse. As expected, the Toxz1 data better predicted human toxicity endpoints than rodent data. Non-animal tests are often faster and cheaper, as well as more accurate and reliable (Balijepalli and Sivaramakrishan, 2017; Bracken, 2009; Gamer et al., 2017; Krul, 2014; NIH, 2008 (Hartung, 2013 (Hartung, 2007 (Hartung, , 2010 Leist et al., 2012 ) . The very concept of the use of animal data as a useful standard is fundamentally flawed, as no species is truly representative of any other (Hartung, 2009; Wang & Gray, 201s; Perlman, 2016) . Indeed the ability of rats to predict for carcinogenicity in mice has been shown to be useful in less than 60% of cases (Gray et al., 1995) . (Judson et al., 2013 (Scott, 2016 (Zerhouni and Hamburg, 2016 (Zerhouni and Hamburg, 2016) . (Malloy, 2016 (Basketter et al., 2012) . However, without an effective top-down (i.e., gov ernment-led) (Archibald, Drake and Coleman, 2015) .
Similarly, tamoxifen was almost lost as a cancer treatment because it causes liver tumors in rats
Furthermore, the same technology is able to identify many other liver-toxic drugs that were missed by animal testing (Xu et al., 2008). -Following the trial of TGN1412, a method using human cells was rapidly developed to model the cytokine storm experienced by the volunteers (Steb bings et al., 2007 ). -The us government's initiative, Toxicolo gy in the 21st Century (Toxz1), has tested 10,000 chemicals using a panel of human cell-based assays (National Center for Advancing Translational Sciences, 2016). These are automated high-throughput screening assays that expose cells to chemicals and then screen them for changes that could suggest toxic effects. The use of this pan el of assays enabled the identification of important safety aspects of drugs and chemicals "markedly better" than toxicity tests in animals
A Way Forward: Pragmatic Evaluation
The need for better ways to protect the public from the ever-increasing epidem ic of AD Rs is so urgent that a new approach to implementing more predictive methods is critical. This is now widely recognized and much attention is
Regulatory (van der Meer, 2014 (National Research Council, 2007) .
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